thalidomide has been researched along with Lymphoma, Primary Effusion in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Lymphoma, Primary Effusion: A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pomalidomide (Pom) is an immunomodulatory drug that has efficacy against Kaposi's sarcoma, a tumor caused by Kaposi's sarcoma-associated herpesvirus (KSHV)." | 1.62 | Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2. ( Aisabor, AI; Davis, DA; Jaeger, HK; Shrestha, P; Stream, A; Yarchoan, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shrestha, P | 1 |
| Davis, DA | 1 |
| Jaeger, HK | 1 |
| Stream, A | 1 |
| Aisabor, AI | 1 |
| Yarchoan, R | 1 |
| Patil, A | 1 |
| Manzano, M | 1 |
| Gottwein, E | 1 |
| Gopalakrishnan, R | 1 |
| Matta, H | 1 |
| Tolani, B | 1 |
| Triche, T | 1 |
| Chaudhary, PM | 1 |
3 other studies available for thalidomide and Lymphoma, Primary Effusion
| Article | Year |
|---|---|
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Topics: Angiogenesis Inhibitors; B7-2 Antigen; Gene Expression Regulation, Neoplastic; Humans; Intercellular | 2021 |
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Topics: Casein Kinase Ialpha; Cell Line, Tumor; CRISPR-Cas Systems; Down-Regulation; Gene Expression Regulat | 2018 |
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, | 2016 |